Agglomerate behaviour of fluticasone propionate within dry powder inhaler formulations

被引:23
|
作者
Le, V. N. P. [1 ,2 ]
Robins, E. [3 ]
Flament, M. P. [1 ,2 ]
机构
[1] Univ Lille Nord France, Coll Pharm, Lille, France
[2] INSERM U 1008, Lille, France
[3] APTAR Pharma, F-27100 Le Vaudreuil, France
关键词
Gas permeation; DPI performance; Fluticasone; Agglomerates; Powder aerosolisation; IN-VITRO DEPOSITION; SALMETEROL XINAFOATE; LACTOSE CARRIER; PARTICLE-SIZE; RESPIRABLE PARTICLES; AEROSOL DISPERSION; SURFACE-PROPERTIES; DRUG; INHALATION; MIXTURES;
D O I
10.1016/j.ejpb.2011.12.004
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Due to their small size, the respirable drug particles tend to form agglomerates which prevent flowing and aerosolisation. A carrier is used to be mixed with drug in one hand to facilitate the powder flow during manufacturing, in other hand to help the fluidisation upon patient inhalation. Depending on drug concentration, drug agglomerates can be formed in the mixture. The aim of this work was to study the agglomeration behaviour of fluticasone propionate (FP) within interactive mixtures for inhalation. The agglomerate phenomenon of fluticasone propionate after mixing with different fractions of lactose without fine particles of lactose (smaller than 32 pm) was demonstrated by the optical microscopy observation. A technique measuring the FP size in the mixture was developed, based on laser diffraction method. The FP agglomerate sizes were found to be in a linear correlation with the pore size of the carrier powder bed (R-2 = 0.9382). The latter depends on the particle size distribution of carrier. This founding can explain the role of carrier size in de-agglomeration of drug particles in the mixture. Furthermore, it gives more structural information of interactive mixture for inhalation that can be used in the investigation of aerosolisation mechanism of powder. According to the manufacturing history, different batches of FP show different agglomeration intensities which can be detected by Spraytec (R), a new laser diffraction method for measuring aerodynamic size. After mixing with a carrier, Lactohale LH200, the most cohesive batch of FP, generates a lower fine particle fraction. It can be explained by the fact that agglomerates of fluticasone propionate with very large size was detected in the mixtures. By using silica-gel beads as ball-milling agent during the mixing process, the FP agglomerate size decreases accordingly to the quantity of mixing aid. The homogeneity and the aerodynamic performance of the mixtures are improved. The mixing aid based on ball-milling effect could be used to ameliorate the quality of inhalation mixture of cohesive drug, such as fluticasone propionate. However, there is a threshold where an optimal amount of mixing aids should be used. Not only the drug des-aggregation reaches its peak but the increase in drug-carrier adhesion due to high energy input should balance the de-agglomeration capacity of mixing process. This approach provides a potential alternative in DPI formulation processing. (C) 2011 Elsevier B.V. All rights reserved.
引用
收藏
页码:596 / 603
页数:8
相关论文
共 50 条
  • [21] Comparison of the systemic effects of fluticasone propionate and budesonide given by dry powder inhaler in healthy and asthmatic subjects
    Harrison, TW
    Wisniewski, A
    Honour, J
    Tattersfield, AE
    THORAX, 2001, 56 (03) : 186 - 191
  • [22] Preparation and Evaluation of Surface Modified Lactose Particles for Improved Performance of Fluticasone Propionate Dry Powder Inhaler
    Singh, Deepak J.
    Jain, Rajesh R.
    Soni, P. S.
    Abdul, Samad
    Darshana, Hegde
    Gaikwad, Rajiv V.
    Menon, Mala D.
    JOURNAL OF AEROSOL MEDICINE AND PULMONARY DRUG DELIVERY, 2015, 28 (04) : 254 - 267
  • [23] Pharmacokinetic Comparison of a Unit Dose Dry Powder Inhaler with a Multidose Dry Powder Inhaler for Delivery of Fluticasone Furoate
    Mehta, Rashmi
    Moore, Alison
    Riddell, Kylie
    Joshi, Shashidhar
    Chan, Robert
    JOURNAL OF AEROSOL MEDICINE AND PULMONARY DRUG DELIVERY, 2017, 30 (05) : 332 - 338
  • [24] Physical stability of dry powder inhaler formulations
    Shetty, Nivedita
    Cipolla, David
    Park, Heejun
    Zhou, Qi Tony
    EXPERT OPINION ON DRUG DELIVERY, 2020, 17 (01) : 77 - 96
  • [25] Alternative carriers in dry powder inhaler formulations
    Rahimpour, Yahya
    Kouhsoltani, Maryam
    Hamishehkar, Hamed
    DRUG DISCOVERY TODAY, 2014, 19 (05) : 618 - 626
  • [26] Pharmacokinetics of fluticasone propionate and salmeterol delivered as a combination dry powder via a capsule-based inhaler and a multi-dose inhaler
    Mehta, Rashmi
    Daley-Yates, Peter T.
    Jenkins, Kevin
    Bianco, Joseph
    Stylianou, Anastasia
    Louey, Margaret D.
    Chan, Robert H.
    PULMONARY PHARMACOLOGY & THERAPEUTICS, 2014, 29 (01) : 66 - 73
  • [27] FLUTICASONE PROPIONATE AND FLUTICASONE PROPIONATE/SALMETEROL DELIVERED VIA MULTIDOSE DRY POWDER INHALERS FOR PERSISTENT ASTHMA
    Raphael, G.
    Yiu, G.
    Sakov, A.
    Liu, S.
    Caracta, C.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2016, 117 (05) : S63 - S63
  • [28] Fluticasone propionate and fluticasone propionate/salmeterol multidose dry powder inhalers compared with placebo for persistent asthma
    Sher, Lawrence D.
    Yiu, Gloria
    Sakov, Anat
    Liu, Siyu
    Caracta, Cynthia F.
    ALLERGY AND ASTHMA PROCEEDINGS, 2017, 38 (05) : 343 - 353
  • [29] Powder Production and Particle Engineering for Dry Powder Inhaler Formulations
    Lin, Yu-Wei
    Wong, Jennifer
    Qu, Li
    Chan, Hak-Kim
    Zhou, Qi
    CURRENT PHARMACEUTICAL DESIGN, 2015, 21 (27) : 3902 - 3916
  • [30] EFFECT OF LACTOSE FINES ON THE DE-AGGLOMERATION BEHAVIOUR OF DRY POWDER INHALER FORMULATIONS
    Kinnunen, H.
    Huck, D.
    Makein, L.
    Virden, A.
    Shur, J.
    Hebbink, G.
    Price, R.
    JOURNAL OF AEROSOL MEDICINE AND PULMONARY DRUG DELIVERY, 2013, 26 (04) : A259 - A259